Page last updated: 2024-12-07

9-(3-(2-nitro-1-imidazolyl)propylamino)-1,2,3,4-tetrahydroacridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-(3-(2-nitro-1-imidazolyl)propylamino)-1,2,3,4-tetrahydroacridine: RN refers to HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133067
CHEMBL ID539757
SCHEMBL ID8909218
MeSH IDM0245295

Synonyms (9)

Synonym
CHEMBL539757
163714-83-8
9-(3-(2-nitro-1-imidazolyl)propylamino)-1,2,3,4-tetrahydroacridine
9-acridinamine, 1,2,3,4-tetrahydro-n-(3-(2-nitro-1h-imidazol-1-yl)propyl)-, monohydrochloride
thnla 1
thnla-1
SCHEMBL8909218
DTXSID10167653
n-[3-(2-nitroimidazol-1-yl)propyl]-1,2,3,4-tetrahydroacridin-9-amine;hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID216743Cytotoxicity of compound was measured against suspended V79 cells under hypoxic conditions in clonogenic assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216742Cytotoxicity of compound was measured against suspended V79 cells under aerobic conditions in clonogenic assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID228276Concentration required to reduce fluorescence in ethidium bromide displacement assay using EB-DNA complex2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID231440Ratio (HS) of CT50 values in aerobic condition to hypoxic condition (in N2 presence) given as CT50(A)/CT50(H)2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID21048Partition coefficient in octanol/water2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216883In vitro therapeutic index of compound was measured inV79 cells2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.42 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]